Literature DB >> 20001755

Genetic predisposition of life-threatening antiepileptic-induced skin reactions.

Wen-Hung Chung1, Shuen-Iu Hung, Yuan-Tsong Chen.   

Abstract

IMPORTANCE OF THE FIELD: Recent advances in pharmacogenetic studies have uncovered increasingly more genes that predispose individuals to adverse drug reactions. Aromatic antiepileptic drugs (AEDs) are a frequent cause of severe cutaneous adverse reactions (SCAR). A strong genetic association between HLA-B*1502 and carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) has been shown in Han Chinese patients. AREAS COVERED IN THIS REVIEW: This article reviews and updates genetic information associated with CBZ and other AEDs causing SCAR in different ethnic populations. WHAT THE READER WILL GAIN: Independent studies from different countries confirmed that patients carrying the HLA-B*1502 are at high risk of SJS/TEN when exposed to CBZ. The US FDA and similar regulatory agencies in Canada and Taiwan have updated the CBZ drug label to include the genetic information. Available data also suggest that HLA-B*1502 is a risk allele for SJS/TEN caused by other aromatic AEDs with a similar structure to CBZ. TAKE HOME MESSAGE: Screening for HLA-B*1502 allele before starting treatment with CBZ is justified in patients from high-risk populations as recommended by regulatory agencies. Similar chemicals should also be avoided in individuals who test positive for HLA-B*1502.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001755     DOI: 10.1517/14740330903427969

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  20 in total

1.  Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Authors:  Cynthia Haddad; Alexis Sidoroff; Sylvia H Kardaun; Maja Mockenhaupt; Daniel Creamer; Ariane Dunant; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

2.  Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Authors:  W C Tan-Koi; Evelyn S H Lim; Y Y Teo
Journal:  Pharmacogenomics J       Date:  2016-02-23       Impact factor: 3.550

3.  Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

Authors:  Timothy A Yap; Jane N Winter; Lisa Giulino-Roth; Jemma Longley; Juanita Lopez; Jean-Marie Michot; John P Leonard; Vincent Ribrag; Michael T McCabe; Caretha L Creasy; Melissa Stern; Teodora Pene Dumitrescu; Xiaowei Wang; Steve Frey; Jennifer Carver; Thierry Horner; Choon Oh; Ahmed Khaled; Arindam Dhar; Peter W M Johnson
Journal:  Clin Cancer Res       Date:  2019-08-30       Impact factor: 12.531

4.  Drug hypersensitivity: pharmacogenetics and clinical syndromes.

Authors:  Elizabeth J Phillips; Wen-Hung Chung; Maja Mockenhaupt; Jean-Claude Roujeau; Simon A Mallal
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

Review 5.  Carbamazepine for acute and chronic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

7.  Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence.

Authors:  Bhawna Sharma; Raghavendra Bakki Sannegowda; Pankaj Gandhi; Parul Dubey; Ashok Panagariya
Journal:  BMJ Case Rep       Date:  2013-06-11

Review 8.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

Review 9.  Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Eija A Kalso
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

Review 10.  Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Dominic Aldington; Peter Cole; Andrew S C Rice; Michael P T Lunn; Katri Hamunen; Maija Haanpaa; Eija A Kalso
Journal:  Cochrane Database Syst Rev       Date:  2013-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.